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Abstract
Gene-activated scaffolds have been shown to induce controlled, sustained release of functional
transgene both in vitro and in vivo. Bone morphogenetic proteins (BMPs) are potent mediators of
osteogenesis however we found that the delivery of plasmid BMP-2 (pBMP-2) alone was not
sufficient to enhance bone formation. Therefore, the aim of this study was to assess if the use of
a series of modified BMP-2 plasmids could enhance the functionality of a pBMP-2 gene-activated
scaffold and ultimately improve bone regeneration when implanted into a critical sized bone defect
in vivo. A multi-cistronic plasmid encoding both BMP-2 and BMP-7 (BMP-2/7) was employed as
was a BMP-2-Advanced plasmid containing a highly truncated intron sequence. With both
plasmids, the highly efficient cytomegalovirus (CMV) promoter sequence was used. However, as
there have been reports that the elongated factor 1-Į promoter is more efficient, particularly in
stem cells, a BMP-2-Advanced plasmid containing the EF1Į promoter was also tested. Chitosan
nanoparticles (CS) were used to deliver each plasmid to MSCs and induced transient up-
regulation of BMP-2 protein expression, in turn significantly enhancing MSC-mediated
osteogenesis when compared to untreated controls (p<0.001). When incorporated into a bone
mimicking collagen-hydroxyapatite scaffold, the BMP-2-Advanced plasmid, under the control of
the CMV promotor, induced MSCs to produce approximately 2500 µg of calcium per scaffold,
significantly higher (p<0.001) than all other groups. Just 4 weeks post-implantation in vivo, this
cell-free gene-activated scaffold induced significantly more bone tissue formation compared to a
pBMP-2 gene-activated scaffold (p<0.001) as indicated by microCT and histomorphometry.
Immunohistochemistry revealed that the BMP-2-Advanced plasmid accelerated differentiation of
osteoprogenitor cells to mature osteoblasts, thus causing rapid healing of the bone defects. This
study confirms that optimising the plasmid construct can enhance the functionality of gene-
activated scaffolds and translate to accelerated bone formation in a critical sized defect.
Keywords: BMP-2; plasmid; gene delivery; gene-activated scaffold; osteogenesis; bone
regeneration
1. Introduction
Bone morphogenetic proteins (BMPs) are potent mediators of osteogenesis both during bone
formation and fracture healing and are the most commonly used growth factors to stimulate bone
tissue formation experimentally. Indeed, both BMP-2 and BMP-7 are approved for use clinically
[1-5]. However, due to the fast release of extremely high doses of recombinant protein (4.2-8.4
mg) required to enhance bone repair, there have been many reports of adverse side effects
including ectopic bone formation, cytotoxicity, increased incidence of cancer as well as some
reports of inadequate healing [6, 7]. Methods to control the release of these proteins and decrease
the dose to more physiological levels might allow for bone repair while reducing or even
eliminating the risk of side-effects. Non-viral gene therapy can be used to transfect cells with
genes encoding for therapeutic proteins, such as BMPs, inducing the transfected cells to produce
physiological quantities of specific protein in a controllable manner [8, 9]. Furthermore, non-viral
gene delivery can ensure sustained but ultimately transient expression of the therapeutic which
is an important safety aspect associated with gene therapy.
Within our laboratory, we have developed a series of gene-activated scaffold platforms capable
of efficiently delivering nucleic acids to cells [10-15]. In particular, a gene-activated scaffold
comprised of chitosan nanoparticles carrying plasmid DNA (pDNA) incorporated into a collagen
hydroxyapatite scaffold resulted in high transfection efficiency with negligible toxicity [16] and
successful transfection of host cells when implanted in vivo [17] making it highly translatable as it
can be manufactured to be an off-the-shelf product. When used to deliver pDNA encoding both
BMP-2 and vascular endothelial growth factor (VEGF), the gene-activated scaffold significantly
accelerated bone formation over untreated and gene-free scaffold controls [17]. Interestingly, we
found that the delivery of plasmid BMP-2 (pBMP-2) alone was not sufficient to enhance bone
formation, thus we sought to improve the efficiency of the pBMP-2-activated scaffold by
investigating the potential of modified BMP-2 encoding plasmids (Figure 1A).
When first expressed, BMPs are large inactive molecules which must be proteolytically cleaved
in order to activate their specific receptors. Active BMPs exist as dimers, molecular structures
with two sub-units. They can exist as homodimers, where both sub-units are identical, such as
BMP-2, and also as heterodimers, where the sub-units are different, for example BMP-2/4 and
BMP-2/7. While both types are active, some studies have demonstrated that heterodimers such
as BMP-2/4 and BMP-2/7 are more active than homodimers [18-20]. For this reason, we sought
to investigate the use of a multi-cistronic plasmid encoding BMP-2 and BMP-7 (Figure 1B) which
may induce expression of BMP-2/7 heterodimers and enhance the efficiency of the gene-
activated scaffold [20].
To ensure maximum efficiency of a plasmid, strategies that allow for fast transcription and more
efficient translation of gene to protein can be employed [21]. Genes are made up of protein-coding
regions called exons, and non-coding regions called introns which are subsequently removed by
spliceosomes before mature messenger RNA (mRNA) leaves the nucleus [22, 23]. During gene
transcription, introns as well as exons are copied, increasing the time and energy required to form
mRNA [24]. Furthermore, during translation of mRNA to protein, codons are translated into amino
acids which subsequently form proteins. Synonymous codons can have the same amino acid
coding potential, however, there is evidence of preferential use within a group of synonymous
codons [25]. Genes that are regularly and highly expressed are typically made up of codons that
can be decoded by abundant transfer RNAs (tRNAs) while rarely expressed genes show no
preference or contain codons that require rare tRNAs [26]. Therefore, by choosing codons that
are used often in place of rarely used codons, referred to as codon optimisation, protein
expression can be significantly enhanced [27]. In a previous study, to streamline transcription
while also increasing protein production, an artificial highly truncated intron of 96 bases was
inserted into the BMP-2 gene and codon optimisation was performed. This has led to faster
transcription of the encoded gene and enhanced protein production and this novel plasmid is
referred to as pBMP-2-Advanced [28] (Figure 1C).
Finally, the promoter sequence in a plasmid also has an effect on transcription efficiency, with the
cytomegalovirus (CMV) promoter being the most commonly used due to its ability to drive high
levels of mRNA transcription [29]. However, the elongation factor 1Į (EF1Į) promoter has also
been shown to be an efficient alternative particularly in mesenchymal stem cells (MSCs) [30]. To
test which promoter sequence was more efficient in promoting transcription of the BMP-2 gene,
two different versions of the pBMP-2-Advanced plasmid were tested, containing either the CMV
or the EF1Į promoter [28] (Figure 1D).
Figure 1: Plasmid maps of different BMP-2 encoding plasmids tested in this study.
The objective of this study was to investigate if using a series of modified BMP-2 plasmids could
enhance the efficacy of a pBMP-2 gene-activated scaffold. Using previously optimised chitosan
(CS) nanoparticles for gene delivery [16], we initially compared the modified plasmids; pCMVBMP-
2/7, pCMVBMP-2-Adv, and pEF1ĮBMP-2-Adv to a previously used pCAGBMP-2 construct and
assessed BMP-2 protein production by transfected MSCs, and BMP-2 protein functionality by
quantifying MSC osteogenesis. The CS nanoparticles carrying each plasmid were then
incorporated into collagen-hydroxyapatite bone-mimicking scaffolds [31], thus forming gene-
activated scaffolds, and the effect of each plasmid on MSC osteogenesis was assessed. Finally,
cell-free gene-activated scaffolds were implanted into critical sized calvarial defects using an
established rat model and bone healing at the early time-point of four weeks was analysed to
assess the ability of the gene-activated scaffolds to accelerate bone formation.
2. Materials and Methods
2.1. Comparison of BMP-2 protein production and functionality following transfection with
modified BMP-2 plasmids
2.1.1 Plasmid propagation
Plasmid DNA (pDNA) encoding human bone morphogenetic protein-2, under the control of a
chimeric CMV-beta actin promoter (CAG), was kindly donated by Prof. Kazihusa Bessho, Kyoto
University, Japan [9] and compared to a series of BMP-2 constructs developed in the Ludwig
Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, namely, pBMP-2/7 [20],
pBMP-2-Advanced (both under the control of the CMV promoter) and pBMP-2-Advanced under
the control of the EF1Į promoter [28]. Green fluorescent protein pDNA was used as a ‘non-
osteogenic’ control plasmid and was purchased from Lonza. All pDNA was propagated in Top10
competent E.coli cells (Invitrogen) and purified and collected following amplification using an
Endotoxin free Maxi-prep kit (Qiagen, UK).
2.1.2 Chitosan-pDNA nanoparticle formulation
Oligomeric chitosan (Mw 7.3kDa; DD >97%) was supplied by Novamatrix, FMC Biopolymer,
Norway. Nanoparticles were formulated by electrostatic interaction between cationic chitosan and
anionic pDNA. Nanoparticles were allowed to equilibrate for 30 min at room temperature before
use. The ratio of chitosan to pDNA (N/P ratio) was kept constant at 20. The pDNA dose was
varied from 0.5 µg to 10 µg in Figure 2 and the optimal dose of 2 µg was chosen for all further
experiments [16]. For each experiment, seven groups were assessed as outlined in Table 1
below.
Table 1: Groups included in each experiment
Group Denoted Function
Untransfected cells Untransfected Control
Empty chitosan nanoparticles CS-Empty Control
Chitosan nanoparticles carrying pGFP (CMV promoter) CS-pCMVGFP Control
Chitosan nanoparticles carrying pBMP-2 (CAG promoter) CS-pCAGBMP-2 Test
Chitosan nanoparticles carrying pBMP-2/7 (CMV promoter) CS-pCMVBMP-2/7 Test
Chitosan nanoparticles carrying pBMP-2-Advanced (CMV
promoter)
CS-pCMVBMP-2-Adv Test
Chitosan nanoparticles carrying pBMP-2-Advanced (EF1Į
promoter)
CS-pEF1ĮBMP-2-Adv Test
2.1.3 Mesenchymal stem cell culture
MSCs, isolated from rat bone marrow, were expanded in Dulbecco's Modified Eagles Medium
supplemented with 2% penicillin/streptomycin, 10% FBS (Labtech, UK), 1% glutamax
(Biosciences, Ireland) and 1% non-essential amino acids (Biosciences, Ireland). Cells were
passaged at 70-90% confluency and expanded to passage 5 for all experiments.
2.1.4 Mesenchymal stem cell transfection in 2D culture
MSCs were seeded at a density of 5x104 cells per well in 6 well adherent plates (Corning, Costar,
Ireland) 24 h prior to transfection. Media was removed from cells 1 h prior to transfection and cells
were washed in PBS (Sigma-Aldrich, Ireland) and 1 mL of OptiMEM (Gibco, Ireland) was added.
Nanoparticles were made as described in Section 2.1.2 and, following complexation, OptiMEM
was added in a 1:1 ratio to the nanoparticle mixture to produce the transfection medium of which
500 µL was added to each well. After 4 h, transfection media was removed, cells were washed
twice in PBS and growth media was replenished.
2.1.5 Enzyme-linked Immunosorbent Assay (ELISA)
ELISAs (R&D Systems, Biotechne, UK) were used to quantify the levels of BMP-2 expressed by
cells transfected with each variant of BMP-2 plasmid as well as for all control groups. The cell
culture supernatant was collected and analysed at days 1, 3, 7 and 14. Assays were carried out
according to the manufacturer’s instructions and the absorbance of each sample was read at 450
nm using a Varioskan Flash multimode plate reader (Fisher Scientific, Ireland). The quantity of
BMP-2 protein present was deduced by calculating against a standard curve.
2.1.6 Assessment of cytotoxicity using MTT assay
MSCs were transfected as described in Section 2.1.4 and an MTT cell proliferation assay kit
(Abcam) was carried out at 3 days post-transfection. This is a metabolic assay where active
cellular enzymes reduce the MTT dye to formazan crystals. Briefly, 50 µL of MTT Reagent was
added to the cells in 50 µL of serum-free media and incubated for 3 h at 37°C. After 3 h 150 µL
of MTT Solvent was added to dissolve the formazan crystals, formed by metabolically active cells,
leaving behind a purple colour.  The intensity of the resulting colour was read at an absorbance
of 570 nm using a reference wavelength of 630 nm using a Varioskan Flash multimode plate
reader (Fisher Scientific, Ireland).
2.1.7 Preparation of cells for fluorescent imaging
pDNA was tagged with a Cy3 fluorophore using a Label IT® Nucleic acid labelling kit (Mirus Bio
LLC) as per manufacturer’s instructions. MSCs were transfected as described in Section 2.1.4.
Five hours post-transfection, the media was removed and the cells were washed with PBS. The
cells were fixed by adding 4% paraformaldehyde for 15 minutes before washing in PBS. To
permeabilise the cells, 0.1% Triton X-100 solution was added before addition of a HCA cell
mask green stain (Invitrogen®) was added to stain the cell membrane and left for 30 minutes
before being removed and washed. Finally, Hoescht 33258 blue stain was added to stain the
nucleus for 5 minutes prior to final washing in PBS. Images were acquired using an automated
Olympus Scan^R screening microscope with a 20x/0.60 NA LUCPLFLN objective.
2.1.6 MSC osteogenesis assay
To assess if the BMP-2 protein produced by transfected cells was functional, an MSC
osteogenesis assay was carried out following transfection as described in Section 2.1.3. After 5
h, OptiMEM was removed and replaced with growth media (Section 2.1.3) for three days before
being changed to osteoinductive media which contained DMEM supplemented with 10% FBS,
1% penicillin/streptomycin, 10 mM ȕ-glycerophosphate, 50 ȝM ascorbic acid 2-phosphate and
100 nM dexamethasone. Media was replaced three times per week until day 14 post-transfection.
Cells were harvested at days 1, 3, 7 and 14 and ALP activity and DNA content was quantified.
Briefly, cells were lysed using 0.2 M sodium carbonate buffer containing 1% Triton X-100. DNA
content was measured using a Quant-iT™ PicoGreen® dsDNA assay (Invitrogen, UK) according
to manufacturer’s protocol and DNA concentration was deduced using a standard curve. The
same cell lysate was used to assess ALP activity using a SensoLyte® pNPP Alkaline
Phosphatase assay kit (Cambridge Biosciences, Ireland). ALP substrate was applied to the
samples and the absorbance measured at 405 nm. ALP concentration was deduced using a
standard curve. Calcium content was quantified at day 14 using a Stanbio calcium assay (Calcium
CPC Liquicolour, Stanbio Inc., USA). Briefly, media was removed and cells were rinsed with 1 ml
of PBS. One ml of 0.5 M HCl was then added to each well and the contents of each well were
scraped into microcentrifuge tubes and left to shake overnight at 4 °C. Calcium levels were then
quantified according to the manufacturer's instructions against a standard curve.
2.2 Comparison of BMP-2 protein functionality following transfection with modified BMP-
2 plasmids on a 3D collagen hydroxyapatite scaffold
2.2.1 Scaffold fabrication
A collagen hydroxyapatite scaffold was prepared as per patented protocol [32]; Briefly, 1.8 g of
collagen (Southern Lights Biomaterials, New Zealand) was blended in 0.5 M HOAc 15,000 rpm
for 90 min. Hydroxyapatite (200wt%) was dissolved separately in 0.5 M HOAc and added slowly
to the collagen slurry (10 mL/h) while maintaining dispersion at 15,000 rpm. Gas was removed
from the slurries using a vacuum pump prior to freeze-drying (Advantage EL, Vis-Tir Co., Gardiner
NY) to a final freezing temperature of -40 °C. The scaffolds were cross linked dehydrothermally
(DHT) at 105 °C for 24 h at 0.05 bar in a vacuum oven (Vacucell 22; MMM, Germany), followed
by chemical cross-linking using a mixture of 6 mM N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) and 5.5 mM N-Hydroxysuccinimide (NHS). Cylindrical
scaffolds (10 mm diameter) were used in transfection experiments. For in vivo experiments,
scaffolds were manufactured with a diameter of 8 mm and a height of 1.5 mm to fit the defect and
reflect the thickness of native calvarial bone.
2.2.2 Gene-activated scaffold fabrication
Scaffolds were manufactured as described in Section 2.2.1 and nanoparticles were made as
described in Section 2.1.2 as optimised previously [16]. CS-pDNA nanoparticles were formulated
at an N/P ratio of 20 containing a 2 ȝg load of each BMP-2 plasmid. Scaffolds were hydrated in
PBS before use and nanoparticles were incorporated by soak-loading onto the scaffold before
MSC seeding. After 24 h the scaffolds were moved to fresh 24 well non-adherent plates in fresh
expansion media for a further 2 days before being changed to osteoinductive media (Section
2.1.6).
2.2.3 Evaluating the effect of different BMP-2 plasmids on MSC osteogenesis in 3D
collagen hydroxyapatite gene-activated scaffolds
Gene-activated scaffolds carrying either: CS-pCAGBMP-2, CS-pCMVBMP-2/7, CS-pCMVBMP-2-Adv
or CS-pEF1ĮBMP-2-Adv as well as untransfected, CS-empty and CS-CMVGFP controls, were
fabricated as described in Section 2.2.2. After 28 days in culture, the scaffolds were removed
from the wells and washed in PBS prior to further analysis. Alizarin red staining was used to
investigate the level of mineralisation within the scaffolds. Samples were fixed with 10% formalin
for 30 minutes and processed overnight using an automatic tissue processor (ASP300, Leica,
Germany). The constructs were embedded in paraffin wax before sectioning. Sections of 5 ȝm
thickness were cut using a rotary microtome (Microsystems GmbH, Germany) and sections were
mounted on poly-L-lysine coated glass slides (Thermo Scientific, Ireland). Samples were
deparaffinised with xylene and rehydrated before being stained in 2% alizarin red for 2-3 min.
Sections were then dehydrated and DPX mountant was used to attach cover slips to the slides.
Digital images of all stained sections were obtained using an imaging system (AnalySIS, Nikon,
Japan) in conjunction with a microscope (Olympus IX51, Olympus, Japan). Calcium content per
scaffold was quantified using a Stanbio calcium assay (Calcium CPC Liquicolour, Stanbio Inc.,
USA) 14 and 28 days post cell seeding. Briefly, media was removed and the scaffolds were placed
in 1 mL of 0.5 M HCl and left shaking overnight at 4 °C. Calcium levels were then quantified
according to the manufacturer's instructions.
2.3 Efficacy of gene-activated scaffold in accelerated repair of critical sized bone defects
in vivo
2.3.1 Surgical procedure
This study was conducted in accordance with protocols approved by the Research Ethics
Committee of the Royal College of Surgeons in Ireland (REC 1205), and an animal licence
granted by the Irish Government Department of Health (Ref. No. B100/4416) in compliance with
EU directive 2010/EU/63. A total of 32 adult male Wistar rats were divided into four groups; (a)
defect was left empty (n=8), denoted ‘untreated’; (b) CHA scaffold alone (n=8), denoted ‘gene-
free scaffold’; (c) CHA scaffold containing CS-pCAGBMP-2 nanoparticles (n=8), denoted ‘CS-
pCAGBMP-2’; and (d) CHA scaffold containing CS-pCMVBMP-2-Adv nanoparticles (n=8), denoted
‘CS-pCMVBMP-2-Adv’. The number of animals used per group to ensure a statistically powerful
study was calculated using G*Power software based on previous studies using the calvarial defect
model [12]. Anaesthesia was induced with intraperitoneal medetomidine hydrochloride (0.3
mg/kg) and ketamine hydrochloride (70 mg/kg) and maintained with inhalational isoflurane (0.5–
2%) and oxygen. The skin of the head was shaved and cleaned using 70% ethanol and
chlorhexidine before the animal was placed in the prone position on a heated aseptic operating
platform prior to draping. A 3 mm sagittal skin incision over the calvarium was made and the soft
tissues dissected using a blunt technique to expose the periosteum. A 7 mm trephine drill was
used to create a 7 mm circular transosseous defect under constant irrigation with 0.9% NaCl.
Scaffolds with a diameter of 8 mm and a height of 1.5 mm were press-fit into the defect and the
periosteum and superficial connective tissue were closed in layers with 3-0 absorbable
monofilament sutures (Monocryl™) and the skin was closed using a topical skin adhesive (n-butyl
cyanoacrylate). Post-operatively, the animals were given a subcutaneous injection of the reversal
agent atipamezole hydrochloride (0.05 mg/kg body weight) to reverse sedation. Animals were
placed in an incubator at 35 ºC until fully recovered. Animals were housed (4 per cage) with ad
libitum access to water, food and environmental enrichment. Antibiotics (enrofloxacin 2.5% - 10
mg/kg) were provided in the drinking water for 3 days post-surgery. At 4 weeks post-surgery, the
animals were euthanised by CO2 asphyxiation and cervical dislocation. A 20 mm x 20 mm section
of the calvarium containing the defect was resected using a dental saw and the tissue was fixed
for 72 h in 10% formalin before being transferred to Dulbecco’s PBS.
2.4.1 Micro-computed tomography
The 20 mm x 20 mm sections of bone were analysed using micro computed tomography (µCT).
Scans were performed on a Scanco Medical 40 MicroCT system (Scanco Medical, Bassersdorf,
Switzerland) with a voxel resolution of 12 µm, a voltage of 70 kVP and a current of 112 ȝA. 3D
reconstruction was performed using the standard Scanco software package with a threshold of
140 in a scale from 0 to 1000, corresponding to a density of 257.99 mg HA/ccm. These settings
have been optimised for the rat calvarial model previously and are routinely used within our group
[12, 17, 33-36]. Volume of interest (VOI) was defined to analyse a 6 mm defect region to assess
healing in the centre of the defect and to exclude any old bone at the defect edges. Repair was
expressed as percentage of bone volume fraction within the defect area.
 2.4.2 Histology and histomorphometry
To confirm the µCT results, both qualitative and quantitative histology was performed on explants.
The explants were first decalcified using Decalcifying Solution-Lite (Sigma-Aldrich, Ireland) for a
total of 13 h before specimens were dehydrated in a graded series of ethanol solutions using an
automated tissue processor, bisected and embedded in single paraffin wax blocks. Sections (7
ȝm thick) were cut from the mid-portion of each sample using a rotary microtome and mounted
on poly-L-lysine coated glass slides. Each section was stained with Haematoxylin and Eosin
(H&E). Haematoxylin stains cell nuclei purple, eosin stains extracellular matrix pink and bone
appears dark pink/red. Images of each specimen were acquired and digitised using transmitted
light microscopic visualization (Nikon Microscope Eclipse 90i with NIS Elements software v3.06,
Nikon Instruments Europe, The Netherlands). Quantitative analysis was performed on n=6
sections from each specimen (n=8 per group). Single blinded histomorphometric analysis was
carried out in order to quantify the healing response from the H&E-stained samples. The defect
margin was identified and any new bone was delineated using colour thresholding which allowed
the quantification of the area of bone nucleation sites (BNS) in each section and calculation of the
mean total area of these sites per group. This was performed using an automated Image J script
[37].
2.4.3 Immunohistochemistry analysis to determine osteoinductive effect of scaffolds
Immunohistochemical staining of paraffin embedded sections was carried out to assess the
osteoinductive effect of the scaffolds on infiltrating endogenous cells by staining for key
checkpoint markers of osteoblast differentiation from progenitor cells. Col1a1 (osteoprogenitor
cells undergoing differentiation), and osteocalcin (mature osteoblasts) were used to identify cells
at both stages of differentiation using rabbit IgG polyclonal antibodies (Santa Cruz Biotech.,
Germany). Two samples per animal were analysed (n=8). Samples were prepared for staining by
deparaffinisation and rehydration, followed by heat-activated citrate-based antigen retrieval.
Samples were then incubated with a 1% H2O2 peroxidase inhibitor (ThermoScientific, Ireland),
before blocking in 5% horse serum (ThermoScientific, Ireland). Samples were then incubated at
4 °C overnight with a 1:100 dilution of each corresponding primary antibody. To complete staining,
a goat IgG Vectastain Elite ABC Kit was used in combination with a DAB Substrate kit (all from
Vector labs, UK) according to manufacturer’s instructions. Finally, the sections were
counterstained using Mayer’s haematoxylin counterstaining and mounted with DPX
(ThermoScientific). Digital imaging was performed using the Nikon Eclipse 90i digital microscope
system and five random sections were acquired for each specimen. Image J software was utilised
to quantify % area of positive DAB staining using the automated pixel saturation method as in
Section 2.4.2.
2.5 Statistical analysis
Results are expressed as mean ± standard deviation. Statistics were carried out using Graphpad
Prism software using a general linear model ANOVA with post-hoc analysis performed for multiple
comparisons. p<0.05 values were considered statistically significant where * p<0.05, ** p<0.01
and *** p<0.001.
3. Results
3.1. Comparison of BMP-2 protein production and functionality following transfection with
modified BMP-2 plasmids
To confirm the optimal pDNA dose required to elicit the highest level of protein production while
simultaneously avoiding cellular toxicity, a pDNA dose response study was carried out. pDNA
doses of 0.5, 1, 2, 5 and 10 µg were delivered to cells at a constant N/P ratio of 20. In Figure 2
A-E the nanoparticles (red) at each pDNA dose can be seen surrounding the cells (green) 5 h
post-transfection and evidence of nanoparticle aggregation can be seen at the higher pDNA
doses of 5 and 10 µg. A pDNA dose of 2 µg/well induced the highest level of BMP-2 protein
production, significantly higher than all other doses, at 3 days post-transfection (Figure 2 F).
Furthermore, at doses of 5 and 10 µg/well, significant cytotoxicity was observed and, likely due to
the sheer number of nanoparticles binding to the cell membrane. Therefore, the optimal pDNA
dose was found to be 2 µg/well at an N/P ratio of 20, confirming previously published data [16].
Figure 2: A pDNA dose response study to determine the optimal pDNA dose for transfection.
Fluorescent microcopy images show increasing evidence of nanoparticle aggregation with
increasing pDNA dose with A) 0.5 µg; B) 1 µg; C) 2 µg; D) 5 µg; and E) 10 µg. The 2 µg pDNA
dose inducing the highest protein production by cells 3 days post-transfection as determined by
ELISA (F) and high concentrations of pDNA (10 µg/well) induced significant cellular toxicity. Data
plotted represents mean ± SD where n=3. Two-way ANOVA followed by Bonferoni post hoc
analysis was performed and *** indicates p<0.001 compared to other doses in F and compared
to untreated controls (represented by the dashed line) in G.
The transient expression of BMP-2 protein by cells over time was also monitored using ELISA
(Figure 3) using the optimal nanoparticle formulation of N/P 20 carrying 2 µg of pDNA. As
expected, there was no increase in BMP-2 protein production by cells that were either
untransfected, transfected with CS-empty or CS-pCMVGFP thus confirming that the CS
nanoparticles are not affecting BMP-2 production. All cells treated with a BMP-2 plasmid
responded by significantly increasing BMP-2 protein production over controls at day 3 and 7
(p<0.05), indicating positive transfection. The CS-pCMVBMP-2/7 treated cells produced
significantly more BMP-2 compared to cells treated with pCAGBMP-2. Encouragingly, both BMP-
2-Adv plasmids significantly enhanced BMP-2 protein production by tranfected cells when
compared to all other groups (p<0.001), and at the earlier time-point of day 3. In particular, the
pCMVBMP-2-Adv proved to be the most efficient plasmid for inducing BMP-2 protein production by
MSCs even when compared to pEF1ĮBMP-2-Adv.
Figure 3: Assessment of BMP-2 protein production by transfected cells. Untransfected cells
were compared to cells treated with CS-empty, CS-pCMVGFP, CS-pCAGBMP-2, CS-pCMVBMP-2/7,
CS-pCMVBMP-2-Adv and CS-pEF1ĮBMP-2-Adv. BMP-2 protein production as monitored by ELISA
at day 1, 3, 7 and 14 post-transfection. Each of the four BMP-2 plasmids induced cells to produce
more BMP-2 protein than controls. The pCMVBMP-2-Adv induced cells to produce significantly
more BMP-2 protein than all other groups at days 3, 7 and 14. Data plotted represents mean ±
SD where n=3. Two-way ANOVA followed by Bonferroni post hoc analysis was performed and *
represents p<0.05 and *** represents p<0.001.
To assess if the BMP-2 protein produced by transfected cells retained its osteoinductive
properties, alkaline phosphatase activity was monitored at days 1, 3, 7 and 14 post-transfection.
There was no increase in ALP activity in untransfected cells cultured in growth media (GM) for 14
days (Figure 4A). When untransfected cells were cultured in osteogenic media (Figure 4B), there
was a significant increase in ALP activity at days 3 and 7 (p<0.05) and similar levels of ALP activity
were seen in cells treated with CS-empty (Figure 4C) and CS-pCMVGFP (Figure 4D). ALP activity
was significantly increased following treatment with each BMP-2 plasmid however pCMVBMP-2-
Adv induced the highest level of ALP activity (Figure 4G). Interestingly, ALP activity peaked at
day 7 in cells transfected with CS-pCAGBMP-2 (Figure 4E) and CS-pCMVBMP-2/7 (Figure 3F) while
an earlier peak in ALP activity at day 3 was evident in the cells transfected with CS-pCMVBMP-2-
Adv and CS-pEF1ĮBMP-2-Adv (Figure 4G and H).
Figure 4: Effect of osteoinductive genes on MSC differentiation as measured by ALP
activity. Untransfected cells in growth media (GM) (A), osteoinductive media (OM) (B) were
compared to cells treated with CS-empty (C), CS-pCMVGFP (D), CS-pCAGBMP-2 (E), CS-pCMVBMP-
2/7 (F), CS-pCMVBMP-2-Adv (G) and CS-pEF1ĮBMP-2-Adv (H), all of which were cultured in
osteoinductive media. ALP activity by MSCs was measured at days 1, 3, 7 and 14 post-
transfection. ALP activity was highest in cells transfected with CS-pCMVBMP-2-Adv. ALP activity
peaked earlier in cells treated with both pBMP-2-Adv plasmids at day 3 with a later peak in ALP
activity evident in cells treated with BMP-2 and BMP-2/7 plasmids. Data plotted represents mean
± SD where n=3. One-way ANOVA followed by Tukey post hoc analysis was performed and *
represents p<0.05 and ** represents p<0.01.
To confirm the osteoinductive effect of the BMP-2 protein produced by cells post-transfection on
MSC osteogenesis, calcium deposition by transfected cells was quantified 14 days after
transfection (Figure 5). As with the ALP activity experiments (Figure 4), all cells were cultured in
osteoinductive media (Section 2.1.6) from day 3 post-transfection with the exception of the
untransfected GM control with GM denoting growth media. As expected, the cells in
osteoinductive media (OM) deposited more calcium than the untransfected cells in GM (p<0.01).
Calcium deposition by the control cells - untransfected in OM, CS-Empty and CS-pCMVGFP, was
similar while all cells transfected with a pBMP-2 plasmid induced significantly more calcium
deposition. Comparing CS-pBMP-2 transfected groups, it was evident that the CS-pCMVBMP-2-
Adv treated cells deposited significantly more calcium than other groups (p<0.001) including the
CS-pEF1ĮBMP-2-Adv group (p<0.05).
Figure 5. Effect of osteoinductive genes on MSC osteogenesis in 2D monolayer as
measured by calcium deposition quantification. Untransfected cells in growth media (GM) and
osteoinductive media (OM) were compared to cells treated with CS-empty, CS-pCMVGFP, CS-
pCAGBMP-2, CS-pCMVBMP-2/7, CS-pCMVBMP-2-Adv and CS-pEF1ĮBMP-2-Adv. Calcium deposition
was quantified 14 days post-transfection. Each condition induced cells to produce significantly
more calcium than untransfected cells in growth media. Each variant of BMP-2 plasmid induced
significantly more calcium deposition than controls without a BMP-2 plasmid. The CS-pCMVBMP-
2-Adv transfected group induced significantly higher levels of calcium deposition compared to all
other groups. Data plotted shows mean ± standard deviation (n=3). One-way ANOVA followed by
Tukey post hoc analysis was performed and * indicates p<0.05, ** p<0.01 and *** p<0.001.
3.2 Comparison of BMP-2 protein functionality following transfection with modified BMP-
2 plasmids on a 3D collagen hydroxyapatite scaffold
Having confirmed the osteoinductive effects of the BMP-2 plasmids in 2D monolayer, and
therefore the ability of the CS nanoparticles to effectively deliver the plasmids to MSCs, we then
tested the efficacy of the modified plasmids when incorporated into a gene-activated collagen
hydroxyapatite (CHA) scaffold. Calcium deposition by cells was used as an indicator of MSC
osteogenesis and was assessed using alizarin red staining at 28 days post-transfection while
calcium content within the scaffolds was quantified at days 14 and 28. As with the 2D experiments,
all cells were cultured in osteoinductive media with the exception of the untransfected GM group.
The images shown in Figure 6 represent full scans of the scaffolds stained with alizarin red 28
days post-transfection. It is evident that there was more positive staining in the scaffolds
containing BMP-2 plasmids but the CS-pCMVBMP-2-Adv treated group appears to have stained
more intensely for mineral. When calcium deposition was quantified (Figure 6), there was no
significant difference in calcium content between untransfected cells in growth versus
osteoinductive media at each time point, reflecting the inherent osteoinductive nature of the
collagen hydroxyapatite scaffold. However, the pBMP-2 treated groups deposited significantly
more calcium than the control groups as is particularly evident at day 28 and again, CS-pCMVBMP-
2-Adv induced significantly more calcium deposition than all other groups.
Figure 6. Effect of osteoinductive genes on MSC osteogenesis in 3D collagen
hydroxyapatite scaffolds as measured by calcium deposition quantification. Untransfected
cells in growth media (GM) and osteoinductive media (OM) were compared to cells treated with
CS-empty, CS-pCMVGFP, CS-pCAGBMP-2, CS-pCMVBMP-2/7, CS-pCMVBMP-2-Adv and CS-
pEF1ĮBMP-2-Adv. Calcium deposition was quantified 14 and 28 days post-transfection. Mineral
deposition (red) is seen in the 4x scans of each scaffold with more mineral evident in the BMP-2
treated groups over the controls. When calcium content was quantified, each condition induced
cells to produce significantly more calcium than untransfected cells in growth media. Each variant
of BMP-2 plasmid induced significantly more calcium deposition than controls without a BMP-2
plasmid. The CS-pCMVBMP-2-Adv transfected group induced significantly higher levels of calcium
deposition compared to all other groups. Data plotted shows mean ± standard deviation (n=3).
Two-way ANOVA followed by Bonferroni post hoc analysis was performed and and * indicates
p<0.05 and *** p<0.001.
3.3 Efficacy of gene-activated scaffold in accelerated repair of critical sized bone defects
in vivo
From the in vitro testing in both 2D monolayer and in 3D gene-activated scaffolds, it was
established that CS-pCMVBMP-2-Adv was the most efficient at inducing MSC osteogenesis. We
then sought to investigate the efficacy of the gene-activated scaffold loaded with CS-pCMVBMP-2-
Adv in vivo in a critical sized calvarial defect (n=8) using an established rat model. To confirm that
this plasmid is more efficient than pCAGBMP-2, we also included CS-pCAGBMP-2 activated
scaffolds as a control (n=8) as well as a gene-free scaffold (n=8) and an untreated control (n=8).
Recently published work has shown that gene-activated scaffolds are capable of accelerating
bone formation [12, 17], thus an early time-point of 4 weeks was chosen for assessment. As 7mm
represents a critical-sized defect, the lack of repair in the untreated group was expected (Figure
7A). The gene-free collagen hydroxyapatite scaffold has previously been shown to heal defects
by 8-12 weeks [35, 38] so the low level of bone formation visible in Figure 7B at this early time-
point was expected. The CS-pCAGBMP-2 activated scaffold induced some de novo bone formation
(Figure 7C); however, the CS-pCMVBMP-2-Adv activated scaffold induced significantly more bone
formation compared to all other groups (Figure 7D). When the new bone volume fraction was
calculated, the CS-pCMVBMP-2-Adv activated scaffold significantly enhanced bone formation
(Figure 7E). Analysis of trabecular number (Figure 7F), trabecular thickness (Figure 7G) and
trabecular spacing (Figure 7H) confirmed this result with a significantly higher number of
trabeculae and thus less space between trabeculae in the animals treated with CS-pCMVBMP-2-
Adv activated scaffold compared to other groups. Trabecular thickness did not vary between
groups.
Figure 7. MicroCT analysis of bone repair in critical sized bone defects after 4 weeks.
Critical size (7 mm) bone defects in the rat calvarium were A) untreated; or B) treated with a gene-
free scaffold; C) a CS-pCAGBMP-2 activated scaffold; or D) a CS-pCMVBMP-2-Adv activated
scaffold. Tissue was harvested 4 weeks post-implantation and new bone formation and quality
was quantified using microCT. Representative reconstructed images show enhanced bone
formation in the CS-pCMVBMP-2-Adv scaffold group compared to control groups and when
quantified, this was a significantly higher amount of new bone volume fraction (E). The quality of
bone was also improved as indicated by trabecular number (F), trabecular thickness (G) and
trabecular spacing (H). Data plotted shows mean ± standard deviation (n=8). One-way ANOVA
followed by Tukey post hoc analysis was performed and * indicates p<0.05 and *** p<0.001.
Histological analysis of the calvarial tissue explants was consistent with the microCT results.
When stained using H&E, the untreated defect explants had minimal new bone within the defect
(pink) and consisted mainly of fibrous tissue (Figure 8A). More bone nucleation sites were evident
in the gene-free and CS-pCAGBMP-2 activated scaffolds but the majority of the tissue was fibrous
in nature and the scaffold was visible (Figure 8B and C). In contrast, animals treated with the CS-
pCMVBMP-2-Adv activated scaffolds have large areas filled with new bone (Figure 8D). The area
of new bone was quantified using an automated Image J programme based on pixel intensity
(Figure 8E) and confirmed that the CS-pCMVBMP-2-Adv activated scaffold induced significantly
more bone formation compared to the other groups (p<0.05 to p<0.001). While there was no
significant difference between the untreated, gene free scaffold and CS-pCAGBMP-2 activated
scaffold groups, the results show a trend towards greater healing in treated versus untreated
groups with untreated < gene-free scaffold < CS-pCAGBMP-2 activated scaffold < CS-pCMVBMP-2-
Adv activated scaffold.
Figure 8. Histological analysis of bone repair in critical sized bone defects after 4 weeks.
Representative H&E images of explants from calvarial defects at 4x and 20x magnification. H&E
staining indicates bone in dark pink. A) Untreated; B) Gene-free scaffold; C) CS-pCAGBMP-2
activated scaffold; D) CS-pCMVBMP-2-Adv activated scaffold. Histomorphological analysis using
an automated pixel intensity method (E) confirmed that the CS-pCMVBMP-2-Adv activated scaffold
significantly enhanced new bone formation compared to CS-pCAGBMP-2 activated scaffolds and
controls after 4 weeks (F). Data plotted shows mean ± standard deviation (n=8). One way ANOVA
followed by Tukey post hoc analysis was performed and * indicates p<0.05, ** p<0.01 and ***
p<0.001.
Immunohistochemistry was then performed to further analyse the process of bone formation of
each of the groups. Col1a1 is a marker of early stage bone formation, being expressed by
differentiating osteoprogenitor cells, while osteocalcin is a marker of late stage bone formation,
being expressed by mature osteoblasts. Samples were stained using antibodies targeting Col1a1
(Figure 9, top panel) and osteocalcin (Figure 9, bottom panel) and clear differences were evident
between groups. The explants from untreated animals (Figure 9A) did not stain positively for either
Col1a1 or osteocalcin, indicating that healing has not begun to any notable level. As this is a
critical sized defect and with the lack of bone formation evident from microCT and histological
analysis (Figures 7 and 8), this result is consistent with the rest of the study. There was positive
staining for both markers in explants from animals treated with gene-free scaffolds (Figure 9B),
CS-pCAGBMP-2 activated scaffolds (Figure 9C) and CS-pCMVBMP-2-Adv activated scaffolds
(Figure 9D) although more positive staining is clearly evident in the latter. Using a similar
automated Image J programme based on pixel intensity as described in Figure 8, positive staining
was quantified. Animals treated with the gene-free scaffolds and CS-pCAGBMP-2 activated
scaffolds contained significantly more Col1a1 than untreated controls (p<0.05 and p<0.01
respectively) while in explants from animals treated with CS-pCMVBMP-2-Adv activated scaffolds,
Col1a1 staining was significantly higher than all other groups (p<0.001) (Figure 9E). The same
trend was evident when positive staining for osteocalcin was quantified although no significant
differences were found between untreated, gene-free scaffolds and CS-pCAGBMP-2 activated
scaffolds. Explants from animals treated with CS-pCMVBMP-2-Adv activated scaffolds had
significantly more osteocalcin present compared to all other groups (Figure 9F).
Interestingly, there was more positive staining for Col1a1 versus osteocalcin in the gene-free
scaffolds which may indicate that the bone healing process was at an earlier stage (Figure 9G).
This result is consistent with the hypothesis that gene-activated scaffolds can accelerate bone
healing as well as previous work which showed healing of defects after 8-12 weeks using the
gene-free scaffold [35, 38]. Conversely, there was more positive staining for osteocalcin versus
Col1a1 in the CS-pCMVBMP-2-Adv activated scaffold which indicates that healing is at a later
stage. Taken together, this study confirms that optimising the plasmid construct can translate to
increased protein formation and confer enhanced therapeutic functionality to the gene-activated
scaffold.
Figure 9. Immunohistochemistry analysis of bone repair in critical sized bone defect after
4 weeks. Representative images of explants from calvarial defects following
immunohistochemical staining for Col1a1 (top row), an early stage marker of bone formation; and
osteocalcin (bottom row), a late stage marker of bone formation at 20x magnification. A)
Untreated; B) Gene-free scaffold; C) CS-pCAGBMP-2 activated scaffold; D) CS-pCMVBMP-2-Adv
activated scaffold. Using an automated Image J programme based on pixel intensity, positive
Col1a1 (E) and osteocalcin (F) staining was quantified showing significantly higher expression of
bone matrix marker in CS-pCMVBMP-2-Adv activated scaffolds. The ratio of Col1a1 positive
staining versus osteocalcin positive staining indicates that the gene-activated scaffolds are
accelerating bone repair (G). Data plotted shows mean ± standard deviation (n=8). One way
ANOVA followed by Tukey post hoc analysis was performed and * indicates p<0.05, ** p<0.01
and *** p<0.001.
4. Discussion
BMP-2 delivery for bone repair has a gained a lot of bad press due to adverse side effects reported
following uncontrolled release of supraphysiological doses of recombinant protein [39, 40] which
are required due to the short half-life of proteins in physiological conditions. Delivering genes
encoding for the BMP-2 protein to host cells, instead of high doses of protein, circumvents the
requirement for high dosing regimes as the cells begin to produce the required protein
themselves. Gene delivery can be used to manipulate cells to produce therapeutic proteins
themselves, thus controlling the release of physiological quantities of protein over time. The
combination of gene delivery with tissue engineered biomaterial scaffolds allows for localised
delivery of therapeutic to the defect site, thus limiting off-target side effects as well as providing a
template for new tissue formation.  The gene-activated scaffold system described in this paper is
highly translatable as the base collagen hydroxyapatite scaffold has already undergone signficant
preclinical testing and is currently being used to treat defects in human patients [35, 36, 41-44].
The chitosan nanoparticles have been shown to be biocompatible and biodegradable unlike many
polymer or lipid-based non-viral gene delivery vectors while maintaining a high transfection
efficiency [45, 46]. Furthermore, previous work within our group has shown that the gene-
activated scaffold has a good safety profile as the gene therapeutic was retained at the defect
site, and was capable of accelerating bone repair in a rodent calvarial model of critical-sized bone
defects when both pCAGBMP-2  and  pCMVVEGF were delivered.  However, the efficacy of a
pCAGBMP-2 gene-activated scaffold on its own was low in comparison [17]. The aim of this study
was to investigate if improved BMP-2 plasmids could increase the efficiency of the gene-activated
scaffold system and enhance bone repair in critical-sized defects.
The first objective of this study was to compare BMP-2 protein expression and functionality
following transfection of MSCs with each of the BMP-2 plasmids. The use of a multi-cistronic
plasmid was assessed to determine if heterodimeric BMP-2/7 expression enhanced bone
formation over homodimeric BMP-2 expression [20]. The results show that pCMVBMP-2/7 delivery
did not enhance BMP-2 production over pCAGBMP-2, however, this may be due to heterodimer
formation rather than low expression of BMP-2 protein. This result is in agreement with previous
studies which showed low BMP-2 production following transfection with the same pCMVBMP-2/7
plasmid and may be due to an inability of the ELISA kit to detect the heterodimeric form of BMP-
2/7 [20, 47]. Interestingly, the level of BMP-7 produced by pBMP-2/7 transfected cells was 5-fold
higher than BMP-2 expression post-transfection with pCMVBMP-2/7 (Supplementary Figure 1), in
line with previous studies [19, 20] indicating that perhaps during post-transcriptional modifications,
the cells are producing more BMP-7 homodimers than BMP-2 homodimers or BMP-2/7
heterodimers. The pCMVBMP-2-Adv and pEF1ĮBMP-2-Adv plasmids both contained a highly
truncated artifical intron sequence and codon optimisation was performed to enhance
transcription rate and translation of BMP-2 protein. Subsequently, the pCMVBMP-2-Adv plasmid in
particular induced faster and higher BMP-2 production by cells compared to pCAGBMP-2,
pCMVBMP-2/7 and even pEF1ĮBMP-2-Adv reaching a peak of approximately 30 ng/mL at days 3
and 7. In contrast, here and in previous studies, peak protein expression was observed at day 10
post-transfection when pCAGBMP-2 was used [17]. This indicates that the modifications to the
BMP-2 gene carried out in the construction of the BMP-2-Advanced plasmids accelerated
transcription and translation rates and the CMV promoter outperformed the EF1Į promoter. Most
encouragingly, the level of protein production by MSCs transfected with the non-viral CS-
pCMVBMP-2-Adv was comparable to recently reported results delivering the BMP-2 gene using an
adenoviral vector [48].
The BMP-2 protein produced by transfected cells was functional, with increased ALP activity by
MSCs transfected with each BMP-2 encoding plasmid. Interestingly, ALP activity in cells
transfected with both BMP-2-Advanced plasmids peaked at the earlier time-point of day 3
compared to the later peak at day 7 in cells transfected with pCAGBMP-2  and  pCMVBMP-2/7.
Calcium deposition was also highest in cells treated with pCMVBMP-2-Adv. These results indicate
that insertion of a highly truncated intron sequence into the BMP-2 gene, along with codon
optimisation, resulted in more efficient transcription and translation of the BMP-2 gene leading to
earlier and higher protein production and earlier osteogenic response by cells following
transfection with pCMVBMP-2-Adv.
The results from experiments carried out in 2D remained consistent when the plasmids were
incorporated into collagen hydroxyapatite (CHA) scaffolds. The CHA scaffold was already shown
to be osteoinductive due to the presence of hydroxyapatite crystals [41] but by loading the scaffold
with CS nanoparticles carrying each BMP-2 plasmid, the osteoinductive potential of the scaffold
was significantly enhanced. Alizarin red staining and calcium quantification showed that the CS-
pCMVBMP-2-Adv activated scaffold was the most osteoinductive with approximately 2500 µg of
calcium deposited by MSCs after 28 days. This result surpasses recent reports using the scaffold
to deliver pBMP-2 with pVEGF [12, 17] as well as previous papers delivering rhBMP-2 [35, 36],
highlighting the efficiency of the pCMVBMP-2-Adv plasmid.
Due to the efficiency of the CS-pCMVBMP-2-Adv activated scaffold in vitro, it was taken forward for
implantation into a 7 mm calvarial defect in a rodent model and compared to CS-pCAGBMP-2
activated scaffolds, gene-free scaffolds, and untreated controls. This model was chosen as it is
well established within our group and allows for direct comparison between different scaffolds
with and without additional therapeutics. Furthermore, as the calvarium is not load-bearing,
variability between animals can be reduced although testing in large load-bearing defects such
as the femur remains a requirement towards translation of these products. In the calvarial model,
the 7mm defect is well established as being of a critical-size [49] and consistent with this, no
healing was observed in the empty defect group. MicroCT and histomorphometry analysis at 4
weeks post-implantation showed that a significantly higher quantity of new bone was present
within the defect in animals treated with the CS-pCMVBMP-2-Adv activated scaffold compared to
the other groups. The bone was also of higher quality to that of control groups as indicated by
trabecular number. The results at this early time-point are impressive as most previous studies
do not show a similar level of healing until 6-8 weeks post-implantation [50, 51]. Furthermore, the
results are comparable to a recent study using chitosan films loaded with five times the dose of
pBMP-2 (10 µg versus 2 µg used in this study) [52]. Another study using chitosan nanoparticles
to deliver pBMP-2 within a chitosan hydrogel showed promising results although the defect was
smaller (5 mm versus 7 mm in this study) and the methods used to determine new bone formation
were qualitative rather than quantitative, making it difficult to draw comparisons [53].
Of most interest in this study was the difference in bone formation observed between the gene-
activated scaffolds loaded with a BMP-2 plasmid versus the BMP-2-Advanced plasmid. The CS-
pCAGBMP-2 activated scaffold induced low levels of bone formation, no different to the gene-free
scaffolds or indeed the untreated controls. While somewhat surprising, it may be that these
treatments require more time to exert an osteoinductive effect. From previous work within our
group, it was shown that the CHA scaffold can induce bridging of critical sized defects at 8 weeks
post-implantation [38]. As was shown by the in vitro data, cells transfected with CS-pCAGBMP-2
took longer to express BMP-2 protein, increase ALP activity, or deposit calcium compared to CS-
pCMVBMP-2-Adv transfected cells, therefore it is a reasonable assumption that the osteoinductive
response of host cells to the CS-pCAGBMP-2 activated scaffold might be delayed. To investigate
further, immunohistochemistry was carried out looking at early (Col1a1) and late (osteocalcin)
stage markers of bone formation [54]. As hypothesised, more active bone formation was
promoted by the CS-pCMVBMP-2-Adv scaffold compared to the other groups. However, there was
more Col1a1 positive staining in the CS-pCAGBMP-2 activated scaffold compared to the untreated
control, indicating that there was some bone formation taking place. Interestingly, in the CS-
pCMVBMP-2-Adv activated scaffold group, there was more osteocalcin present than Col1a1 which
may indicate that the induced bone is at a more mature stage. Conversely, in the CS-pCAGBMP-2
activated scaffold and gene-free scaffold treated animals, there was more Col1a1 than
osteocalcin present indicating that bone formation was at an earlier stage. These results support
the hypothesis that the BMP-2-Advanced plasmid can accelerate bone formation.
5. Conclusions
This study revealed that by using a modified BMP-2 plasmid, transcription and translation of the
BMP-2 protein can be enhanced leading to earlier and higher levels of BMP-2 protein expression,
increased ALP activity at an earlier time-point and enhanced calcium deposition. In vitro results
were translated in vivo with significantly more bone formation observed at the early time-point of
4 weeks in defects treated with pCMVBMP-2-Adv compared to the pCAGBMP-2, and demonstrated
that this result was due to delayed expression of lower levels of the bone markers Col1a1 and
osteocalcin. Taken together, this study confirms that by optimising the plasmid construct, it is
possible to accelerate and increase protein production and confer enhanced functionality to the
gene-activated scaffold. This system essentially acts as a single-treatment therapeutic factory,
inducing host cells which readily infiltrate the scaffold to produce BMP-2 at physiological levels,
resulting in enhanced bone repair. Furthermore, the transient protein expression induced by the
non-viral vector overcomes concerns associated with gene therapy and reduces the risk of off-
target side effects. The gene-free collagen hydroxyapatite scaffold used in this study has already
undergone rigorous in vitro and in vivo [31, 42, 55] testing and is now in human clinical use
(marketed as HydroxyColl™ by SurgaColl Technologies) making this next generation gene-
activated scaffold a highly translatable therapy for critical sized or non-union bone defects.
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Supplementary Figures
Supplementary Figure 1. Protein production by cells transfected with pBMP-2/7. BMP-2 and
BMP-7 protein production as monitored by ELISA at day 3, 7, 10 and 14 post-transfection with
CS-pCMVBMP-2/7. BMP-7 production was approximately 5-fold higher than BMP-2 production.
Data plotted represents mean ± SD where n=3 and *** represents p<0.001.
